Logo.jpg
Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
May 27, 2021 08:30 ET | Celsion CORP
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Logo.jpg
Celsion Corporation Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 08:00 ET | Celsion CORP
Focus on Immuno-Oncology and Next-Generation Vaccines is Supported with a Strong Balance Sheet Conference Call Begins at 10:00 a.m. Eastern Time Today LAWRENCEVILLE, N.J., May 14,...
Logo.jpg
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
May 11, 2021 08:00 ET | Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...
Logo.jpg
Celsion Corporation to Hold First Quarter 2021 Financial Results and Business Update Conference Call on Friday, May 14, 2021
May 07, 2021 08:30 ET | Celsion CORP
LAWRENCEVILLE, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Logo.jpg
CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
March 31, 2021 08:00 ET | Celsion CORP
LAWRENCEVILLE, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
Logo.jpg
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
March 19, 2021 08:45 ET | Celsion CORP
Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet Conference Call Begins at 11:00 a.m. Eastern Time Today ...
Logo.jpg
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
March 12, 2021 08:45 ET | Celsion CORP
LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Logo.jpg
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
March 02, 2021 08:45 ET | Celsion CORP
LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Logo.jpg
Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference
February 26, 2021 08:45 ET | Celsion CORP
LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
Logo.jpg
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
February 25, 2021 08:45 ET | Celsion CORP
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or...